Neo‐PATH, a single‐arm, nonrandomized trial, investigated preoperative atezolizumab combined with docetaxel, trastuzumab, and pertuzumab in stage II or III HER2‐positive breast cancer patients. This evidence concerns the gene ERBB2 and breast cancer.